Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1990 Nov;137(5):1059–1064.

Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.

W Domagala 1, L Woźniak 1, J Lasota 1, K Weber 1, M Osborn 1
PMCID: PMC1877664  PMID: 2173410

Abstract

Two hundred sixty-two invasive breast carcinomas dating from 1979 to 1984 were tested for vimentin and keratin on formaldehyde-fixed paraffin-embedded sections. None of 26 lobular carcinomas expressed vimentin. Vimentin expression in 10% or more of tumor cells was found in 78% of medullary (14 of 18), in 16% of ductal not otherwise specified (NOS) (35 of 214), and in two of four mucinous carcinomas. A further seven tumors showed vimentin expression in less than 1% to 10% of the cells. Vimentin was expressed in tumor cells of 30% (28 of 93) of grade III invasive ductal NOS carcinomas versus 7% (7 of 105) of grade II and 0% of grade I carcinomas (0 of 10). Vimentin was found to be preferentially expressed in tumors growing in broad, often anastomosing bands or sheets with extensive necrosis, scanty supportive stroma, high nuclear grade, and numerous mitoses. The authors conclude that vimentin is not detected in lobular carcinomas, but is preferentially expressed in medullary and in high-grade ductal NOS breast carcinomas.

Full text

PDF
1062

Images in this article

1063Figure 1
on p.1063

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azumi N., Battifora H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. Am J Clin Pathol. 1987 Sep;88(3):286–296. doi: 10.1093/ajcp/88.3.286. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cattoretti G., Andreola S., Clemente C., D'Amato L., Rilke F. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer. 1988 Apr;57(4):353–357. doi: 10.1038/bjc.1988.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Charpin C., Andrac L., Vacheret H., Habib M. C., Devictor B., Lavaut M. N., Toga M. Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections. Cancer Res. 1988 Aug 1;48(15):4368–4374. [PubMed] [Google Scholar]
  5. Domagala W., Lasota J., Bartkowiak J., Weber K., Osborn M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol. 1990 Jan;136(1):219–227. [PMC free article] [PubMed] [Google Scholar]
  6. Ferrari S., Battini R., Kaczmarek L., Rittling S., Calabretta B., de Riel J. K., Philiponis V., Wei J. F., Baserga R. Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol. 1986 Nov;6(11):3614–3620. doi: 10.1128/mcb.6.11.3614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gerdes J., Pickartz H., Brotherton J., Hammerstein J., Weitzel H., Stein H. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol. 1987 Dec;129(3):486–492. [PMC free article] [PubMed] [Google Scholar]
  8. Gröne H. J., Weber K., Gröne E., Helmchen U., Osborn M. Coexpression of keratin and vimentin in damaged and regenerating tubular epithelia of the kidney. Am J Pathol. 1987 Oct;129(1):1–8. [PMC free article] [PubMed] [Google Scholar]
  9. Meyer J. S., Lee J. Y. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed] [Google Scholar]
  10. Osborn M., Debus E., Weber K. Monoclonal antibodies specific for vimentin. Eur J Cell Biol. 1984 May;34(1):137–143. [PubMed] [Google Scholar]
  11. Osborn M., Mazzoleni G., Santini D., Marrano D., Martinelli G., Weber K. Villin, intestinal brush border hydrolases and keratin polypeptides in intestinal metaplasia and gastric cancer; an immunohistologic study emphasizing the different degrees of intestinal and gastric differentiation in signet ring cell carcinomas. Virchows Arch A Pathol Anat Histopathol. 1988;413(4):303–312. doi: 10.1007/BF00783022. [DOI] [PubMed] [Google Scholar]
  12. Raymond W. A., Leong A. S. Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium. J Pathol. 1989 Apr;157(4):299–306. doi: 10.1002/path.1711570406. [DOI] [PubMed] [Google Scholar]
  13. Raymond W. A., Leong A. S. Vimentin--a new prognostic parameter in breast carcinoma? J Pathol. 1989 Jun;158(2):107–114. doi: 10.1002/path.1711580205. [DOI] [PubMed] [Google Scholar]
  14. Ridolfi R. L., Rosen P. P., Port A., Kinne D., Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977 Oct;40(4):1365–1385. doi: 10.1002/1097-0142(197710)40:4<1365::aid-cncr2820400402>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  15. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  16. Thorpe S. M., Rose C., Rasmussen B. B., Mouridsen H. T., Bayer T., Keiding N. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res. 1987 Nov 15;47(22):6126–6133. [PubMed] [Google Scholar]
  17. Viac J., Reano A., Brochier J., Staquet M. J., Thivolet J. Reactivity pattern of a monoclonal antikeratin antibody (KL1). J Invest Dermatol. 1983 Oct;81(4):351–354. doi: 10.1111/1523-1747.ep12519941. [DOI] [PubMed] [Google Scholar]
  18. Wargotz E. S., Silverberg S. G. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol. 1988 Nov;19(11):1340–1346. doi: 10.1016/s0046-8177(88)80290-9. [DOI] [PubMed] [Google Scholar]
  19. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES